Update on the use of zoledronic acid in the management of osteoporosis

被引：11

作者：

Reid D.M. ^{[1
]}

机构：

[1] Department of Rheumatology, School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, Foresterhill

来源：

Current Osteoporosis Reports | 2010年 / 8卷 / 3期

关键词：

Acute phase reaction; Annual infusion; Atrial fibrillation; Atypical fractures; Bone mineral density; Glucocorticoid osteoporosis; Hip fracture; Impaired renal function; Intravenous bisphosphonate; Male osteoporosis; Nonvertebral fracture; Osteonecrosis of the jaw; Postmenopausal osteoporosis; Reduced mortality; Vertebral fracture;

D O I：

10.1007/s11914-010-0021-4

中图分类号：

学科分类号：

摘要：

Zoledronic acid is a third-generation bisphosphonate that is administered as an annual infusion, and it has some interesting features. After a successful preclinical development program, it has undergone extensive testing in postmenopausal osteoporosis where it has substantial antifracture efficacy at the vertebral, nonvertebral, and hip sites. It has been shown to be effective in reducing vertebral and nonvertebral fractures in patients who had recently suffered a femoral neck fracture, and has demonstrated efficacy in preventing and reversing bone loss in glucocorticoid osteoporosis. The drug is generally well tolerated, although it has been shown to cause significant acute phase reactions occurring in the first 3 days, mainly after the first infusion. Care must be taken to avoid using the drug in those with significantly impaired renal function, although initial concerns about a relationship to atrial fibrillation and osteonecrosis of the jaw have so far proved to be unfounded. © 2010 Springer Science+Business Media, LLC.

引用

页码：145 / 150

页数：5

共 58 条

[1]

Reid I.R., Miller P., Lyles K., Et al., Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease, N Engl J Med, 353, pp. 898-908, (2005)

[2]

Hosking D., Lyles K., Brown J.P., Et al., Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate, J Bone Miner Res, 22, pp. 142-148, (2007)

[3]

Russell R.G., Xia Z., Dunford J.E., Et al., Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy, Ann N y Acad Sci, 1117, pp. 209-257, (2007)

[4]

Delmas P.D., Adami S., Strugala C., Et al., Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study, Arthritis Rheum, 54, pp. 1838-1846, (2006)

[5]

Eisman J.A., Civitelli R., Adami S., Et al., Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study, J Rheumatol, 35, pp. 488-497, (2008)

[6]

Harris S.T., Blumentals W.A., Miller P.D., Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies, Curr Med Res Opin, 24, pp. 237-245, (2008)

[7]

Hornby S.B., Evans G.P., Hornby S.L., Et al., Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats, Calcif Tissue Int, 72, pp. 519-527, (2003)

[8]

Glatt M., Pataki A., Evans G.P., Et al., Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid, Osteoporos Int, 15, pp. 707-715, (2004)

[9]

Gasser J.A., Ingold P., Venturiere A., Et al., Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat, J Bone Miner Res, 23, pp. 544-551, (2008)

[10]

Brouwers J.E., Ruchelsman M., Rietbergen B., Bouxsein M.L., Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats, Osteoporos Int, 20, pp. 1377-1384, (2009)

← 1 2 3 4 5 6 →